If you are benefiting from a GLP-1 medication, that benefit is realand it should be weighed alongside any potential side effects with the support of a healthcare provider
Therefore, DPP-4 inhibitors extend the half-life of endogenous GLP-1 lead to a 2threefold elevation of endogenous GLP-1 concentration, and provide beneficial effects in T2DM [110, 111]
Mol Psychiatry 2016 Oct
Written by FormBlends Editorial Research Prepared by FormBlends Editorial Research
Alexander JT, Staab EM, Wan W et al (2021) The longer-term benefits and harms of glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis
Dues collection is $5,000 over budget, publications income was over budget by $2,125, and miscellaneous income was over budget by $19,092